

COVID-19 Testing for Clinical Trials

As experts in infectious disease assays, Eurofins Clinical Trial Solutions offers a broad array of testing solutions for biomarker detection, immunogenicity, and other safety and efficacy assessments to support anti-viral and vaccine candidate clinical programs.

We also offer several validated molecular and serology tests for SARS-CoV-2, including both qualitative and quantitative QPCR assays, as well as an automated ELISA-based antibody test, a SARS CoV-2 next generation sequencing assay for infection confirmation, and a full-length genome sequencing assay for variant detection.

Amongst Eurofins Clinical Trial Solutions' COVID-19/SARS COV-2 testing options, our RT-PCR assay was reported by the US FDA to be the most sensitive assay (180 NDU/mL) of the 117 evaluated.*

COVID-19 TESTING PORTFOLIO

| TEST NAME | TECHNOLOGY | SAMPLE | UTILITY |
|---|-------------------------------|---|---|
| Coronavirus SARS-CoV-2 RT-PCR Test* | PCR (RT-PCR) | Nasopharyngeal swab (NP), nasal wash, BAL | Qualitative to detect active infection |
| Coronavirus SARS-CoV-2 RT-qPCR Test (quantitative) | PCR (RT-PCR) | Saliva (Isohelix or OMNIgene®), NP swab, serum/plasma | Quantitative to determine viral load |
| SARS-CoV-2 Full-length Genome Sequencing | Whole Genome Sequencing (WGS) | NP swab in saline, VTM/UTM, add'l sample types TBD | Variant detection under ISO 17025 |
| Coronavirus SARS-CoV-2 Neutralizing Antibody (NAb) Test | ELISA | serum/plasma | Indication of adaptive immunity to SARS-CoV-2 |

*US FDA SARS-CoV-2 Reference Panel Comparative Data: Sensitivity Mean Estimates of the EUA authorized molecular diagnostic tests using the FDA SARS CoV-2 Reference Panel. <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data>

Performance Characteristics or the SARS CoV2 Spike gene sequencing assay (from validation):


Accuracy & Precision:

| ID | Expected Variants* | Detected Variants | Concordance |
|----------|--|--|-------------|
| Sample 1 | A23403G/D614G | A23403G/D614G | 100% |
| Sample 2 | A23403G/D614G | A23403G/D614G | 100% |
| Sample 3 | A23403G/D614G | A23403G/D614G | 100% |
| Sample 4 | T22162C/Y200Y; A23403G/D614G | T22162C/Y200Y; A23403G/D614G | 100% |
| Sample 5 | C21575T/L5F; C23185T/F541F; A23403G/D614G T24085C/L841L | C21575T/L5F; C23185T/F541F; A23403G/D614G T24085C/L841L | 100% |

*Obtained from 5 different samples with 3 replicates each

Spike gene variant detection


(Variant allele frequency is uniform across all calls*)




*Variants were detected in 2.85×10^9 copies/mL samples using the Whole Genome Sequencing assay in a Germany lab (Eurofins Genomic Lab)

COVID-19 Testing for Clinical Trials

S gene coverage depth



Fraction Covered



Sensitivity (limit of detection/LOD):

| Estimated Conc. (copies/mL) | Average Reads | Median Depth of Coverage |
|-----------------------------|---------------|--------------------------|
| 15,000 | 120,703 | 4,229 |
| 10,000 | 104,897 | 3,194 |
| 6,667 | 112,825 | 2,692 |

Depth of coverage of S gene. (Input: 6,667 copies per mL)
>100x coverage of entire S gene sequence

Summary of Additional Viral Assays

- Immunogenicity (Viral T-Cell Immunity Panel (TCIP))
- Viral Load Monitoring (qPCR- NP swab, eye swab, fecal, tissue, saliva)
- Serology Testing (IgG EIA, IgM EIA, Total Antibody EIA)
- Sequencing & Genotyping (AVR)
- Custom Assay Designs (Client-Specific) – ELISA, PCR, ELISpot
- Vector copy number (PK)
- Viral shedding assays (qPCR)
- TCID50 infectivity (reflex)

WHY USE EUROFINS CLINICAL TRIAL SOLUTIONS

- We offer a comprehensive menu of real-time PCR and sequencing assays for viral and bacterial pathogen detection and monitoring.
- Our R&D team has extensive experience performing pathogen load monitoring, antiviral resistance assessment, sequencing and other pathogen characterization for clinical trials.
- Eurofins Clinical Trial Solutions specializes in custom development, validation and optimization of qPCR and genotyping assays for pathogens.



Eurofins Viracor BioPharma
18000 West 99th Street
Lenexa, KS 66219 USA
Tel +1 800 305 5198
Fax +1 816 347 0143

eurofins-viracor.com
clinicaltrials@vbp.eurofinus.com

Contact us today to discover how the Eurofins Clinical Trial Solutions team can make the difference in your projects.

All trademarks mentioned herein are the property of Eurofins or their respective owners. Lit No. MM 1102 REV1 0223 Printed in the USA.

© 2023 Viracor Eurofins BioPharma is an independent member of Eurofins Clinical Trial Solutions.